FDA Tackles Drug Competition to Improve Patient Access
Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry
of lower-cost alternatives. The agency published a list of off-patent, off-exclusivity branded drugs without approved generics, and also implemented, for the
first time, a new policy to expedite the review of generic drug applications where competition is limited.
